此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

接受铂类化疗的妇科癌症患者补充蛋白质、亮氨酸和维生素 D (PRODIGY-1)

2026年11月2日 更新者:Emanuele Cereda、Fondazione IRCCS Policlinico San Matteo di Pavia

接受一线铂类化疗的妇科癌症患者补充蛋白质、亮氨酸和维生素 D

Open clinical trial addressing the effect of a nutritional support based on whey proteins, leucine and vitamin D on muscle mass and multiple anticancer treatment-related endpoints in patients with gynecologic cancer receiving first-line platinum-based chemotherapy (adjuvant or curative). A comparison to matched historical controls will be performed to address potential evidence of efficacy to be investigated in a subsequent randomized trial.

研究概览

研究类型

介入性

注册 (估计的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Italy
      • Pavia、Italy、意大利、27100
        • 招聘中
        • IRCCS San Matteo
        • 首席研究员:
          • Emanuele Cereda, MD, PhD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • histologically confirmed diagnosis of gynecologic cancer (ovarian, uterine, cervical);
  • indication for a first-line chemotherapy (adjuvant or curative) with a platinum-based regimen to be used by investigator's choice within the framework of good clinical practice and in agreement with current Italian Association of Medical Oncology guidelines;
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
  • signed informed consent.

Exclusion Criteria:

  • age <18 years
  • ECOG performance status >2
  • indication to or ongoing artificial nutrition support
  • known kidney failure (previous glomerular filtration rate <30 ml/min);
  • known liver failure (Child B or C)
  • endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis)
  • decompensated diabetes
  • indications related to the study product: more than 10 µg (400 IU) of daily Vitamin D intake from medical sources More than 500 mg of daily calcium intake from medical sources; adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study.
  • known allergy to milk, milk products or other components of the proposed interventions
  • inclusion in other nutritional intervention trials
  • patients refusal

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Muscle-targeted nutritional support

Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

其他名称:
  • 针对肌肉的营养支持
其他:Standard of care

Control group receiving no nutritional intervention or on-demand non muscle-targeted nutritional intervention such as nutritional counseling with or without oral nutritional supplement

Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in muscle mass area
大体时间:18 weeks

Change in muscle mass at the end of first-line platinum-based chemotherapy (adjuvant or curative) evaluated with computed tomography scan at the level of the third lumbar vertebra

18 weeks

次要结果测量

结果测量
措施说明
大体时间
Skeletal muscle mass
大体时间:18 weeks

Change in skeletal muscle mass during the study evaluated with bioimpedance vectorial analysis

18 weeks
Body weight
大体时间:18 weeks

Change in body weight during the study (assessed at each chemotherapy cycle)

18 weeks
Protein-calorie intake
大体时间:18 weeks

Change in protein-calorie intake during the study (assessed at each chemotherapy cycle)

18 weeks
Handgrip strength
大体时间:18 weeks

Change in handgrip strength

18 weeks
Treatment-related moderate-severe adverse events as assessed by Common Terminology Criteria for Adverse Events [CTCAE v5.0]
大体时间:18 weeks

Difference in the incidence of grade >=3 toxicity, according to CTCAE v5.0. Toxicity is graded on 0-5 ordinal scale where a higher score means a worse outcome.

18 weeks
Adherence to treatment schedule
大体时间:18 weeks

Difference in the proportion of patients completing the treatment schedule as planned

18 weeks
Total dose of chemotherapy administered
大体时间:18 weeks

To be calculated as the percentage of chemotherapy dose administered with respect to the treatment plan

18 weeks
Patients requiring unplanned hospitalization
大体时间:18 weeks

The rate of patients requiring unplanned hospitalization (one or more) during the study will be calculated

18 weeks
Tolerance to nutritional support
大体时间:18 weeks

Occurrence of events of gastrointestinal intolerance

18 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Emanuele Cereda, MD, PhD、Fondazione IRCCS Policlinico San Matteo

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月8日

初级完成 (估计的)

2027年3月30日

研究完成 (估计的)

2027年3月30日

研究注册日期

首次提交

2023年9月29日

首先提交符合 QC 标准的

2023年10月14日

首次发布 (实际的)

2023年10月18日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅